Decrements in health‐related quality of life associated with adverse events in people with diabetes
Aim To estimate the decrements in health‐related quality of life (QoL) associated with a range of adverse events to inform assessments of the effects of diabetes treatments on QoL in contemporary clinical practice. Methods Participants' QoL utility measures were derived from the five‐level Euro...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2022-03, Vol.24 (3), p.530-538 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 538 |
|---|---|
| container_issue | 3 |
| container_start_page | 530 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 24 |
| creator | Keng, Mi Jun Leal, Jose Bowman, Louise Armitage, Jane Mihaylova, Borislava |
| description | Aim
To estimate the decrements in health‐related quality of life (QoL) associated with a range of adverse events to inform assessments of the effects of diabetes treatments on QoL in contemporary clinical practice.
Methods
Participants' QoL utility measures were derived from the five‐level EuroQoL five‐dimensional (EQ‐5D‐5L) questionnaires completed by 11 683 ASCEND participants (76% of 15 480 recruited). EQ‐5D utility decrements associated with cardiovascular (myocardial infarction, coronary revascularization, transient ischaemic attack [TIA], ischaemic stroke, heart failure), bleeding (gastrointestinal [GI] bleed, intracranial haemorrhage, other major bleed), cancer (GI tract cancer, non‐GI tract cancer), and microvascular events (end‐stage renal disease [ESRD], amputation) were estimated using a linear regression model following adjustment for participants' sociodemographic and clinical risk factors.
Results
Amputation was associated with the largest EQ‐5D utility decrement (−0.206), followed by heart failure (−0.185), intracranial haemorrhage (−0.164), GI bleed (−0.091), other major bleed (−0.096), ischaemic stroke (−0.061), TIA (−0.057), and non‐GI tract cancer (−0.026). We were unable to detect decrements in EQ‐5D utility associated with myocardial infarction, coronary revascularization, GI tract cancer, or ESRD. EQ‐5D utility was lower at older age, independent of other factors.
Conclusion
These estimated decrements in QoL associated with cardiovascular, bleeding, cancer, and other adverse events can inform assessments of the overall value of treatments in patients with diabetes. |
| doi_str_mv | 10.1111/dom.14610 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9361007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2607307081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4430-dec531b6a107499a303f4401cd88fbe5b091bc758ec34275a179a6ae15f89c263</originalsourceid><addsrcrecordid>eNp1kc1O3DAURi1UxF9Z9AWqSN2UReA6dhJnU6kCWpBAbMracpybjpETD3Yyo9nxCDwjT1J3MoNKJby5lr6jo2t_hHyicErjOWtcd0p5QWGHHMTJUsqy4sP6nqWigmyfHIbwAACciXKP7DMuioJBdUDwArXHDvshJKZPZqjsMHt5evZo1YBN8jgqa4ZV4trEmhYTFYLTZh0tzTBLVLNAHzDBxVYxRze3OKWNUTUOGD6S3VbZgMebeUTuf1z-Or9Kb-5-Xp9_v0k15wzSBnXOaF0oCiWvKsWAtZwD1Y0QbY15DRWtdZkL1IxnZa5oWalCIc1bUemsYEfk2-Sdj3WHjY47eWXl3JtO-ZV0ysi3SW9m8rdbyIrF34MyCr5uBN49jhgG2Zmg0VrVoxuDzIoIQQmCRvTLf-iDG30fnxepTHAohcgidTJR2rsQPLavy1CQf8uTsTy5Li-yn__d_pXcthWBswlYGour903y4u52Uv4BdPWlqA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2628407882</pqid></control><display><type>article</type><title>Decrements in health‐related quality of life associated with adverse events in people with diabetes</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Keng, Mi Jun ; Leal, Jose ; Bowman, Louise ; Armitage, Jane ; Mihaylova, Borislava</creator><creatorcontrib>Keng, Mi Jun ; Leal, Jose ; Bowman, Louise ; Armitage, Jane ; Mihaylova, Borislava ; ASCEND Study Collaborative Group ; ASCEND Study Collaborative Group</creatorcontrib><description>Aim
To estimate the decrements in health‐related quality of life (QoL) associated with a range of adverse events to inform assessments of the effects of diabetes treatments on QoL in contemporary clinical practice.
Methods
Participants' QoL utility measures were derived from the five‐level EuroQoL five‐dimensional (EQ‐5D‐5L) questionnaires completed by 11 683 ASCEND participants (76% of 15 480 recruited). EQ‐5D utility decrements associated with cardiovascular (myocardial infarction, coronary revascularization, transient ischaemic attack [TIA], ischaemic stroke, heart failure), bleeding (gastrointestinal [GI] bleed, intracranial haemorrhage, other major bleed), cancer (GI tract cancer, non‐GI tract cancer), and microvascular events (end‐stage renal disease [ESRD], amputation) were estimated using a linear regression model following adjustment for participants' sociodemographic and clinical risk factors.
Results
Amputation was associated with the largest EQ‐5D utility decrement (−0.206), followed by heart failure (−0.185), intracranial haemorrhage (−0.164), GI bleed (−0.091), other major bleed (−0.096), ischaemic stroke (−0.061), TIA (−0.057), and non‐GI tract cancer (−0.026). We were unable to detect decrements in EQ‐5D utility associated with myocardial infarction, coronary revascularization, GI tract cancer, or ESRD. EQ‐5D utility was lower at older age, independent of other factors.
Conclusion
These estimated decrements in QoL associated with cardiovascular, bleeding, cancer, and other adverse events can inform assessments of the overall value of treatments in patients with diabetes.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.14610</identifier><identifier>PMID: 34866309</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adverse events ; Amputation ; Bleeding ; Brain Ischemia ; Cancer ; cardiovascular disease ; Cerebral infarction ; Congestive heart failure ; Diabetes ; diabetes complications ; Diabetes Mellitus ; Gastrointestinal tract ; health economics ; Health Status ; Heart attacks ; Heart failure ; Hemorrhage ; Humans ; Ischemia ; Microvasculature ; Myocardial infarction ; Original ; Quality of Life ; Risk factors ; Stroke ; Stroke - epidemiology ; Stroke - etiology ; Surveys and Questionnaires ; Transient ischemic attack</subject><ispartof>Diabetes, obesity & metabolism, 2022-03, Vol.24 (3), p.530-538</ispartof><rights>2021 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4430-dec531b6a107499a303f4401cd88fbe5b091bc758ec34275a179a6ae15f89c263</citedby><cites>FETCH-LOGICAL-c4430-dec531b6a107499a303f4401cd88fbe5b091bc758ec34275a179a6ae15f89c263</cites><orcidid>0000-0001-7870-6730 ; 0000-0002-0951-1304 ; 0000-0001-5979-1706</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.14610$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.14610$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34866309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keng, Mi Jun</creatorcontrib><creatorcontrib>Leal, Jose</creatorcontrib><creatorcontrib>Bowman, Louise</creatorcontrib><creatorcontrib>Armitage, Jane</creatorcontrib><creatorcontrib>Mihaylova, Borislava</creatorcontrib><creatorcontrib>ASCEND Study Collaborative Group</creatorcontrib><creatorcontrib>ASCEND Study Collaborative Group</creatorcontrib><title>Decrements in health‐related quality of life associated with adverse events in people with diabetes</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aim
To estimate the decrements in health‐related quality of life (QoL) associated with a range of adverse events to inform assessments of the effects of diabetes treatments on QoL in contemporary clinical practice.
Methods
Participants' QoL utility measures were derived from the five‐level EuroQoL five‐dimensional (EQ‐5D‐5L) questionnaires completed by 11 683 ASCEND participants (76% of 15 480 recruited). EQ‐5D utility decrements associated with cardiovascular (myocardial infarction, coronary revascularization, transient ischaemic attack [TIA], ischaemic stroke, heart failure), bleeding (gastrointestinal [GI] bleed, intracranial haemorrhage, other major bleed), cancer (GI tract cancer, non‐GI tract cancer), and microvascular events (end‐stage renal disease [ESRD], amputation) were estimated using a linear regression model following adjustment for participants' sociodemographic and clinical risk factors.
Results
Amputation was associated with the largest EQ‐5D utility decrement (−0.206), followed by heart failure (−0.185), intracranial haemorrhage (−0.164), GI bleed (−0.091), other major bleed (−0.096), ischaemic stroke (−0.061), TIA (−0.057), and non‐GI tract cancer (−0.026). We were unable to detect decrements in EQ‐5D utility associated with myocardial infarction, coronary revascularization, GI tract cancer, or ESRD. EQ‐5D utility was lower at older age, independent of other factors.
Conclusion
These estimated decrements in QoL associated with cardiovascular, bleeding, cancer, and other adverse events can inform assessments of the overall value of treatments in patients with diabetes.</description><subject>Adverse events</subject><subject>Amputation</subject><subject>Bleeding</subject><subject>Brain Ischemia</subject><subject>Cancer</subject><subject>cardiovascular disease</subject><subject>Cerebral infarction</subject><subject>Congestive heart failure</subject><subject>Diabetes</subject><subject>diabetes complications</subject><subject>Diabetes Mellitus</subject><subject>Gastrointestinal tract</subject><subject>health economics</subject><subject>Health Status</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Ischemia</subject><subject>Microvasculature</subject><subject>Myocardial infarction</subject><subject>Original</subject><subject>Quality of Life</subject><subject>Risk factors</subject><subject>Stroke</subject><subject>Stroke - epidemiology</subject><subject>Stroke - etiology</subject><subject>Surveys and Questionnaires</subject><subject>Transient ischemic attack</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1O3DAURi1UxF9Z9AWqSN2UReA6dhJnU6kCWpBAbMracpybjpETD3Yyo9nxCDwjT1J3MoNKJby5lr6jo2t_hHyicErjOWtcd0p5QWGHHMTJUsqy4sP6nqWigmyfHIbwAACciXKP7DMuioJBdUDwArXHDvshJKZPZqjsMHt5evZo1YBN8jgqa4ZV4trEmhYTFYLTZh0tzTBLVLNAHzDBxVYxRze3OKWNUTUOGD6S3VbZgMebeUTuf1z-Or9Kb-5-Xp9_v0k15wzSBnXOaF0oCiWvKsWAtZwD1Y0QbY15DRWtdZkL1IxnZa5oWalCIc1bUemsYEfk2-Sdj3WHjY47eWXl3JtO-ZV0ysi3SW9m8rdbyIrF34MyCr5uBN49jhgG2Zmg0VrVoxuDzIoIQQmCRvTLf-iDG30fnxepTHAohcgidTJR2rsQPLavy1CQf8uTsTy5Li-yn__d_pXcthWBswlYGour903y4u52Uv4BdPWlqA</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Keng, Mi Jun</creator><creator>Leal, Jose</creator><creator>Bowman, Louise</creator><creator>Armitage, Jane</creator><creator>Mihaylova, Borislava</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7870-6730</orcidid><orcidid>https://orcid.org/0000-0002-0951-1304</orcidid><orcidid>https://orcid.org/0000-0001-5979-1706</orcidid></search><sort><creationdate>202203</creationdate><title>Decrements in health‐related quality of life associated with adverse events in people with diabetes</title><author>Keng, Mi Jun ; Leal, Jose ; Bowman, Louise ; Armitage, Jane ; Mihaylova, Borislava</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4430-dec531b6a107499a303f4401cd88fbe5b091bc758ec34275a179a6ae15f89c263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adverse events</topic><topic>Amputation</topic><topic>Bleeding</topic><topic>Brain Ischemia</topic><topic>Cancer</topic><topic>cardiovascular disease</topic><topic>Cerebral infarction</topic><topic>Congestive heart failure</topic><topic>Diabetes</topic><topic>diabetes complications</topic><topic>Diabetes Mellitus</topic><topic>Gastrointestinal tract</topic><topic>health economics</topic><topic>Health Status</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Ischemia</topic><topic>Microvasculature</topic><topic>Myocardial infarction</topic><topic>Original</topic><topic>Quality of Life</topic><topic>Risk factors</topic><topic>Stroke</topic><topic>Stroke - epidemiology</topic><topic>Stroke - etiology</topic><topic>Surveys and Questionnaires</topic><topic>Transient ischemic attack</topic><toplevel>online_resources</toplevel><creatorcontrib>Keng, Mi Jun</creatorcontrib><creatorcontrib>Leal, Jose</creatorcontrib><creatorcontrib>Bowman, Louise</creatorcontrib><creatorcontrib>Armitage, Jane</creatorcontrib><creatorcontrib>Mihaylova, Borislava</creatorcontrib><creatorcontrib>ASCEND Study Collaborative Group</creatorcontrib><creatorcontrib>ASCEND Study Collaborative Group</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keng, Mi Jun</au><au>Leal, Jose</au><au>Bowman, Louise</au><au>Armitage, Jane</au><au>Mihaylova, Borislava</au><aucorp>ASCEND Study Collaborative Group</aucorp><aucorp>ASCEND Study Collaborative Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decrements in health‐related quality of life associated with adverse events in people with diabetes</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2022-03</date><risdate>2022</risdate><volume>24</volume><issue>3</issue><spage>530</spage><epage>538</epage><pages>530-538</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Aim
To estimate the decrements in health‐related quality of life (QoL) associated with a range of adverse events to inform assessments of the effects of diabetes treatments on QoL in contemporary clinical practice.
Methods
Participants' QoL utility measures were derived from the five‐level EuroQoL five‐dimensional (EQ‐5D‐5L) questionnaires completed by 11 683 ASCEND participants (76% of 15 480 recruited). EQ‐5D utility decrements associated with cardiovascular (myocardial infarction, coronary revascularization, transient ischaemic attack [TIA], ischaemic stroke, heart failure), bleeding (gastrointestinal [GI] bleed, intracranial haemorrhage, other major bleed), cancer (GI tract cancer, non‐GI tract cancer), and microvascular events (end‐stage renal disease [ESRD], amputation) were estimated using a linear regression model following adjustment for participants' sociodemographic and clinical risk factors.
Results
Amputation was associated with the largest EQ‐5D utility decrement (−0.206), followed by heart failure (−0.185), intracranial haemorrhage (−0.164), GI bleed (−0.091), other major bleed (−0.096), ischaemic stroke (−0.061), TIA (−0.057), and non‐GI tract cancer (−0.026). We were unable to detect decrements in EQ‐5D utility associated with myocardial infarction, coronary revascularization, GI tract cancer, or ESRD. EQ‐5D utility was lower at older age, independent of other factors.
Conclusion
These estimated decrements in QoL associated with cardiovascular, bleeding, cancer, and other adverse events can inform assessments of the overall value of treatments in patients with diabetes.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>34866309</pmid><doi>10.1111/dom.14610</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7870-6730</orcidid><orcidid>https://orcid.org/0000-0002-0951-1304</orcidid><orcidid>https://orcid.org/0000-0001-5979-1706</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2022-03, Vol.24 (3), p.530-538 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9361007 |
| source | MEDLINE; Wiley Journals |
| subjects | Adverse events Amputation Bleeding Brain Ischemia Cancer cardiovascular disease Cerebral infarction Congestive heart failure Diabetes diabetes complications Diabetes Mellitus Gastrointestinal tract health economics Health Status Heart attacks Heart failure Hemorrhage Humans Ischemia Microvasculature Myocardial infarction Original Quality of Life Risk factors Stroke Stroke - epidemiology Stroke - etiology Surveys and Questionnaires Transient ischemic attack |
| title | Decrements in health‐related quality of life associated with adverse events in people with diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A17%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decrements%20in%20health%E2%80%90related%20quality%20of%20life%20associated%20with%20adverse%20events%20in%20people%20with%20diabetes&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Keng,%20Mi%20Jun&rft.aucorp=ASCEND%20Study%20Collaborative%20Group&rft.date=2022-03&rft.volume=24&rft.issue=3&rft.spage=530&rft.epage=538&rft.pages=530-538&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.14610&rft_dat=%3Cproquest_pubme%3E2607307081%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2628407882&rft_id=info:pmid/34866309&rfr_iscdi=true |